Previously, as a Manager at Deallus, a global strategy consulting firm for large biopharma clients, he led the Oncology business unit and founded the firm’s East Coast office. As an Investment Director at INKEF Capital, a leading European VC firm, Lucas led the allocation of $120 million in US and European therapeutics start-ups, served on the respective Boards, and realized a number of exits. At INKEF, he was instrumental in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million. He is also the Founder of August Care, developing outcomes-based financial solutions for high-cost precision medicine.
Dr. de Breed holds a PhD in Molecular Oncology from University College London and an MBA from Stanford University. He has also co-authored several scientific papers. He is a Director at Quantum Leap Healthcare, a 501c(3)charitable organization integrating high-impact clinical research with patient care to improve and save lives; a member of the Scientific Advisory Board or Promontory Therapeutics, a clinical stage oncology company; and a member of the Advisory Board of FIRST, an early stage investment fund for cardiovascular and regenerative medicine.